MMP19 and diabetes mellitus: In a meta-analysis of 127 clinical trials of patients with or without diabetes two decades ago10, Casas et al. reported that RASi has a smaller benefit on ESKD than OTHERS with a relative risk of 0.87, CI (0.75, 0.99), but RASi had no additional effect on the eGFR compared to OTHERS during the follow-up period.